YOLFTbeta
Scancell Hldgs Plc

Scancell Hldgs Plc

SCLP · LSE · Healthcare / Biotechnology

81.00GBX+1.00 (+1.25%)

Price History

Full chart

Market Stats

Previous Close80.00
Open80.00
Day Range79.00 – 82.00
52-Week Range9.10 – 29.50
Volume111.35K
Market Cap127.53M
P/E (TTM)0.00
Forward P/E3.54
EPS-0.01
Dividend Yield0.00%
Beta0.69
50-Day Avg9.70
200-Day Avg13.59

About

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Phillip John L'Huillier MBA, Ph.D.
  • Employees60
  • HeadquartersBellhouse Building, Oxford, United Kingdom, OX4 4GD, UK
  • Websitehttps://www.scancell.co.uk

Leadership

  • Dr. Phillip John L'Huillier MBA, Ph.D.CEO & Director · b. 1962
  • Prof. Lindy Gillian Durrant Ph.D.Chief Scientific Officer, Director & Founder · b. 1957
  • Mr. David SchilanskyInterim Chief Financial Officer · b. 1975
  • Dr. Samantha Paston Ph.D.Head of Translational Research
  • Dr. Mandeep SehmiHead of Business Development
  • Dr. Callum ScotthasbeenSenior Vice President of Development
  • Dr. Nermeen Varawalla DPHIL, M.B.A., M.D., Ph.D.Chief Medical Officer · b. 1962
  • Dr. Shamim Kazmi StokesHead of Programme Management
  • Mr. Philip Angell-ManningHead of CMC
  • Mr. Alex HaywardFinance Director & Company Secretary

Financials

Income Statement

Currency: GBP2007-04-302008-04-302009-04-302010-04-302011-04-302012-04-302013-04-302014-04-302015-04-302016-04-302017-04-302018-04-302019-04-302020-04-302021-04-302022-04-302023-04-302024-04-302025-04-30
Total Revenue2.18M231-----00000-0005.27M04.71M
Growth (%)--99.99%----------------100.00%-
Cost of Revenue520.46K241.26K676.00K1.09M849.00K--0021.89K32.58K27.61K21.06K43.00K249.00K740.00K525.00K966.00K1.12M
Gross Profit1.66M-241.00K-676.00K-1.09M-849.00K--00-21.89K-32.58K-27.61K-21.06K-43.00K-249.00K-740.00K4.75M-966.00K3.59M
Gross Margin76.10%-104329.00%--------------90.04%-76.29%
Operating Expense700.73K269.00K215.00K752.00K885.00K--2.50M2.96M3.02M4.52M4.91M6.71M6.74M9.50M13.52M16.67M17.30M18.59M
Operating Income955.27K-510.00K-891.00K-1.84M-1.73M-1.96M-2.18M-2.50M-2.96M-3.04M-4.55M-4.94M-6.73M-6.78M-9.75M-14.26M-11.92M-18.27M-15.00M
Operating Margin43.90%-220779.22%---------------226.14%--318.42%
EBITDA1.08M-422.00K-806.00K-1.78M-1.69M-1.89M-2.11M-2.43M-2.80M-3.01M-4.46M-4.91M-6.69M-6.72M-14.90M-3.75M-12.19M-7.06M-12.71M
EBITDA Margin49.82%-182683.98%---------------231.21%--269.73%
Net Income890.55K-405.00K-786.00K-1.74M-1.65M557.06K-1.90M-2.22M-2.42M-2.58M-3.54M-4.20M-5.63M-5.51M-15.48M-2.06M-11.94M-5.86M-12.27M
Net Income Margin40.93%-175324.68%---------------226.45%--260.50%
R&D--676.00K1.09M849.00K1.22M1.45M1.68M2.00M2.01M2.77M2.85M4.15M4.67M6.41M9.48M11.64M12.87M14.69M
R&D as % of Total Revenue----------------220.93%-311.74%
Interest Expense--0000000000014.00K1.65M2.88M1.22M1.09M1.72M
Interest Expense % of Total Revenue----------------23.05%-36.45%

Balance Sheet

Currency: GBP2005-08-312006-04-302007-04-302008-04-302009-04-302010-04-302011-04-302012-04-302013-04-302014-04-302015-04-302016-04-302017-04-302018-04-302019-04-302020-04-302021-04-302022-04-302023-04-302024-04-302025-04-30
Total Assets1.24M581.00K1.64M1.14M5.42M6.50M4.76M7.26M5.41M9.61M7.36M10.57M7.03M14.64M10.54M10.54M8.82M49.06M30.27M23.58M23.09M
Total Liabilities58.00K40.00K206.21K88.35K167.00K452.00K122.00K284.38K315.11K537.59K603.91K575.65K531.88K696.09K1.21M1.21M1.17M29.57M36.50M27.08M26.93M
Total Equity1.18M541.00K1.43M1.05M5.25M6.05M4.64M6.97M5.09M9.08M6.75M9.99M6.50M13.94M9.34M9.34M19.48M18.11M-6.23M-3.50M-3.83M
Cash742.00K202.00K1.50M997.75K1.52M2.83M1.11M3.53M1.49M5.57M3.06M6.53M2.67M10.30M4.56M4.56M41.11M41.11M19.92M14.82M16.89M
Total Debt---------------129.00K15.39M18.92M21.13M19.87M16.27M
Net Debt---1.50M-997.75K-1.52M-2.83M-1.11M-3.53M-1.49M-5.57M-3.06M-6.53M-2.67M-10.30M-4.56M-4.43M-25.72M-25.66M1.21M5.05M-627.00K

Cash Flow

Currency: GBP2009-04-302010-04-302011-04-302012-04-302013-04-302014-04-302015-04-302016-04-302017-04-302018-04-302019-04-302020-04-302021-04-302022-04-302023-04-302024-04-302025-04-30
Operating Cash Flow-1.06M-1.31M-1.78M859.62K-2.00M-2.09M-2.64M-2.33M-3.85M-4.06M-7.02M-7.03M-7.80M-7.80M-8.14M-15.66M-6.11M
Investing Cash Flow914.00K-70.00K9.00K-11.90K-39.36K6.26K131.51K13.55K-7.63K-8.66K-2.66K12.34K-13.00K-741.00K81.00K178.00K-1.54M
Financing Cash Flow1.66M2.69M48.00K1.57M-6.16M5.79M5.79M11.70M11.70M1.28M1.28M46.08M46.08M-746.00K10.39M9.73M
Capital Expenditure23.00K72.00K043.31K69.39K22.93K61.08K61.08K61.08K11.41K2.66K2.66K27.00K744.00K203.00K177.00K14.00K
Free Cash Flow-1.08M-1.39M-1.78M816.31K-2.07M-2.12M-2.64M-2.33M-3.91M-4.07M-7.02M-7.04M-4.80M-8.55M-8.34M-15.84M-6.12M
FCF to OCF102.17%105.48%100.00%94.96%103.47%101.10%100.00%100.00%101.59%100.28%100.04%100.04%61.50%109.53%102.49%101.13%100.23%

Earnings

Report DateJan 27, 2016Jun 4, 2016Jan 31, 2017Sep 13, 2017Jan 30, 2018Sep 25, 2018Jan 31, 2019Aug 20, 2019Jan 31, 2020Oct 16, 2020Jan 29, 2021Oct 29, 2021Dec 22, 2021Oct 28, 2022Jan 25, 2023Jan 30, 2025Sep 11, 2025Jan 29, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.00-0.00-0.00-0.000.000.000.00
EPS Actual-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.010.00-0.010.00-0.010.00-0.01
Surprise------------------
Timing--Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market---

Key Statistics & Ratios

Market Cap127.53M
Enterprise Value139.21M
Trailing P/E0.00
Forward P/E3.54
PEG Ratio0.00
Price / Sales27.07
Price / Book8.89
EPS-0.01
Book Value-0.008
Revenue (TTM)4.71M
Gross Profit (TTM)4.47M
EBITDA-12.96M
Profit Margin-116.98%
Operating Margin-283.34%
Return on Equity-269.84%
Return on Assets-52.17%
Shares Outstanding1.36B
Shares Float648.32M
Beta0.69
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 21, 20261:10
  • Jul 26, 201110:1